Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
8
×
life sciences
8
×
national blog main
biotech
clinical trials
boston blog main
brexit
europe
europe blog main
falsified medicines
fda
innovation
labeling
mhra
new york blog main
regulations
uk
amgen
boston top stories
national
national top stories
new york
new york top stories
san diego blog main
san diego top stories
achaogen
adams street partners
akcea therapeutics
alirocumab
alnylam pharmaceuticals
antibiotics
anylam pharmaceuticals
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boston
calcitonin gene-related peptide
cardiomyopathy
chronic migraine
crispr
cystic fibrosis
What
medicines
8
×
drug
brexit
charting
choppy
course
dynamic
end
period
plans
post
regulation
regulatory
reveals
transition
uk
alnylam
approved
disease
fda
new
pharmaceuticals
year
ago
akcea
amyloidosis
announced
approval
attr
available
bacteria
based
battle
biopharma
business
cf
cholesterol
class
company
crisis
Language
unset
unknown
Current search:
medicines
×
drugs
×
" life sciences "
×
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines